Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2012


#135201

55pages

Global Markets Direct

$ 2000

In Stock

 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Review, H2 2012

 

Global Markets Directs, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Review, H2 2012', provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutic pipeline. This report provides information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
  • A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

 

Keywords

 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutic Products under Development, Key Players in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Overview, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Assessment

Table of Contents


Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) 8
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics under Development by Companies 10
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Products under Development by Companies 17
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Products under Investigation by Universities/Institutes 18
Companies Involved in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Development 19
Spectrum Pharmaceuticals, Inc. 19
Altor BioScience Corporation 20
Telormedix SA 21
Viventia Biotechnologies Inc. 22
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 29
apaziquone - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
apaziquone - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
TMX-101 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
oportuzumab monatox Intravesical - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CG0070 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ProtoCure Intravesical Instillation Solution - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BCG Connaught - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ALT-803 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TD-6989 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TD-3633 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CEL-031 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Drug Profile Updates 47
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Product Development Milestones 51
Featured News & Press Releases 51
Apr 18, 2012: Celek Pharma To Present Recent Progress On Anticancer Drug, CEL-031, At NCI's Investor Forum 51
Apr 05, 2012: Spectrum Announces Results Of Apaziquone Phase III Clinical Trials 51
Apr 02, 2012: Connaught Strain Of BCG Shows Potential To Treat Non-Muscle-Invasive Bladder Cancer In Phase III Study 52
Mar 19, 2012: Telormedixs TMX-101 Exhibits High Safety In Phase I/II Trial For Non-Muscle Invasive Bladder Cancer 52
Jan 19, 2012: OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium 53


Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55


Number of Products Under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H2 2012 8
Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Spectrum Pharmaceuticals, Inc., H2 2012 19
Altor BioScience Corporation, H2 2012 20
Telormedix SA, H2 2012 21
Viventia Biotechnologies Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 28
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Drug Profile Updates 47


Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H2 2012 8
Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27